Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Phase 1/2
33
about 12 years
18+
1 site in NY
What this study is about
This trial is testing a treatment called super-selective intra-arterial repeated infusion of cetuximab (CTX) in people with newly diagnosed glioblastoma. The treatment will be given after disrupting the blood-brain barrier, along with standard chemotherapy and radiation therapy (STUPP protocol).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Intra-arterial Cetuximab
- 2.Take Intra-arterial Mannitol
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ALIMENTARY TRACT AND METABOLISM
injection (Injection)
Primary: Overall Survival (OS), Progression Free Survival (PFS)
Secondary: Composite overall response rate (CORR) through the Response Assessment in Neuro-Oncology (RANO), Toxicities graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03
Oncology